CRUK/11/043 (via Uni of Warwick): De-ESCALaTE-HPV: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) vs Standard Chemotherapy early and Late Toxicity Events in Human Papilloma Virus Positive oropharyngeal carcinoma

Mehanna, Hisham (Principal Investigator)

Cancer and Genomic Sciences

Short title	CRUK/11/043 (via Uni of Warwick): De-ESCALaTE-HPV: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) vs Standard Chemotherapy early and Late Toxicity Events in Human Papilloma Virus Positive oropharyngeal carcinoma
Status	Finished
Effective start/end date	1/09/12 → 31/08/17

Funding

Cancer Research UK

2 Article

De-escalation after DE-ESCALATE and RTOG 1016: a head and neck cancer InterGroup framework for future de-escalation studies
Mehanna, H., Rischin, D., Wong, S. J., Gregoire, V., Ferris, R., Waldron, J., Le, Q-T., Forster, M., Gillison, M., Laskar, S., Tahara, M., Psyrri, A., Vermorken, J. & Porceddu, S., 1 Aug 2020, In: Journal of Clinical Oncology . 38, 22, p. 2552-2557 7 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
10 Citations (Scopus)

182 Downloads (Pure)
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
Mehanna, H., Robinson, M., Hartley, A., Kong, A., Foran, B., Fulton-Lieuw, T., Dalby, M., Mistry, P., Sen, M., O'Toole, L., Al Booz, H., Dyker, K., Moleron, R., Whitaker, S., Brennan, S., Cook, A., Griffin, M., Aynsley, E., Rolles, M., De Winton, E., & 18 othersChan, A., Srinivasan, D., Nixon, I., Grumett, J., Leemans, C. R., Buter, J., Henderson, J., Harrington, K., McConkey, C., Gray, A., Dunn, J., De-ESCALaTE HPV Trial Group, Pettit, L., Nankivell, P., Bryant, J., Sharma, N., Spruce, R. & Brooks, J., 5 Jan 2019, In: The Lancet. 393, 10166, p. 51-60 10 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
286 Citations (Scopus)

236 Downloads (Pure)